Niemann-Pick C1 (NPC1) is a critical 13-transmembrane lysosomal protein essential for intracellular cholesterol transport and serves as the obligate intracellular receptor for Filoviruses, including Ebola and Marburg viruses. Developing therapeutics targeting NPC1—whether small molecule chaperones for Niemann-Pick Type C disease or biologics blocking viral entry—demands physiologically relevant reagents that preserve native conformation and glycosylation patterns.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NPC1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NPC1 Luminal Domain C (Loop 2) ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View NPC1 Products |
| Gene Delivery | NPC1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Preserves 13-transmembrane native conformation. |
View NPC1 Products |
| Benchmark Ab | Anti-NPC1 Recombinant Antibody Recombinant positive control for binding and neutralization assays. |
View NPC1 Products |
| Validator | NPC1 siRNA Set For knockdown verification in cholesterol accumulation assays. |
View NPC1 Products |
| Related Target A | NPC2 Soluble lysosomal cholesterol binding protein; synergistic partner in intracellular lipid transport. |
View NPC2 Products |
| Related Target B | Ebola Virus Glycoprotein (Ebola GP) Primary viral ligand that binds directly to NPC1 Domain C inside the host endosome. |
View Ebola GP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-pass Membrane Protein Conformation | Lentiviral transduction systems enable stable overexpressing host cell lines, avoiding misfolding issues of synthetic membranes. |
| Endosomal Glycosylation Requirements | HEK293 mammalian expression system ensures native glycosylation of the luminal Domain C, critical for viral GP binding. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies included for assay standardization. |
| False Positives | Validated siRNA sets included for functional target knockdown verification. |
Live NPC1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic development surrounding NPC1 is bifurcated into two high-value sectors: gene therapies/chaperones targeting Niemann-Pick Type C (NPC) orphan disease, and host-directed broad-spectrum antivirals targeting the NPC1-Filovirus interface. While enzyme replacement therapies face blood-brain barrier limitations, next-generation modalities are shifting toward AAV-mediated gene restoration and highly selective small-molecule chaperones that stabilize mutant NPC1 (such as the prevalent I1061T mutation) without disrupting physiological cholesterol homeostasis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV) | Passage Bio, Amicus Therapeutics | Niemann-Pick Disease Type C | Overexpression Validation (Need Lentivirus for stable cell line generation) |
| Small Molecule Chaperones | IntraBio, Orphazyme | Neurodegenerative Lysosomal Storage | Mutant Protein Assays (Need sequence-verified mutant NPC1 domains) |
| Monoclonal Antibodies / Fusion Proteins | Academic Collaborations, USAMRIID | Ebola / Marburg Virus Infection | In vitro Blockade Assay (Need high-purity Domain C-Fc & Ebola GP) |